Anne Schmitt-Hoffmann
Basilea Pharmaceutica Ltd.
P.O. Box 3255
Basel 4002
Switzerland
Name/email consistency: high
- Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Schmitt-Hoffmann, A., Roos, B., Heep, M., Schleimer, M., Weidekamm, E., Brown, T., Roehrle, M., Beglinger, C. Antimicrob. Agents Chemother. (2006)
- Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Schmitt-Hoffmann, A., Roos, B., Maares, J., Heep, M., Spickerman, J., Weidekamm, E., Brown, T., Roehrle, M. Antimicrob. Agents Chemother. (2006)
- Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Schmitt-Hoffmann, A., Roos, B., Schleimer, M., Sauer, J., Man, A., Nashed, N., Brown, T., Perez, A., Weidekamm, E., Kovács, P. Antimicrob. Agents Chemother. (2004)
- Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Schmitt-Hoffmann, A., Nyman, L., Roos, B., Schleimer, M., Sauer, J., Nashed, N., Brown, T., Man, A., Weidekamm, E. Antimicrob. Agents Chemother. (2004)
